Two foremost technologies of nuclear imaging equipment market used for cancer and neurological imaging are PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) scanners. Nuclear imaging is a nascent imaging technology that uses a small quantity of radioactive substance linked to compounds used by the body's cells or compounds that attach to tumor cells. Using special detection apparatus, the radioactive substances can be located in the body to see when and where they concentrate and this technique has the capacity of improving disease prevention, clinical research, medical diagnosis, and treatment. PET generates computerized images of chemical alteration, such as sugar metabolism, which take place in the tissue. Usually, the patient is given an injection of a combination of sugar and radioactively labeled sugar, radioactive sugar accumulates on the tumor in the body if it is present and can be traced with the help of a scanner. However, in SPECT a small dose of radioactive material is injected in the vein of the patient and can be traced by the use of a scanner to check the blood flow to tissue and chemical reactions in the body. Rising awareness levels among physicians and clinical researchers regarding the benefits of nuclear imaging coupled with increasing application areas such as cases in oncology, and neurological diseases are the factors driving PET and SPECT market. Furthermore, increasing geriatric population and expanding horizon of applications in SPECT and PET imaging owing to constant discovery and developments of new radiopharmaceuticals are driving the diagnostic imaging market.
On the basis of technology, the nuclear imaging equipment market can be segmented as PET, PET/CT, SPECT, and SPECT/CT. PET accounted for the highest market share owing to its ability to provide high resolution images, it is mainly used in oncology as the images provided gives comprehensive information of the tumor. SPECT has the maximum share in cardiology. Furthermore, lack of availability of technetium-99m used for SPECT is one of the factors for its low market share. On the basis of application the market can be segmented as oncology, neurology, and cardiology.
North America, Europe, Asia Pacific, and RoW are few key regions analyzed in the report. North America has the highest share of the PET and SPECT market globally closely followed by Europe. Asia Pacific nuclear imaging equipment market is expected to grow at a rapid pace due to a rise in the aging population, an increase in chronic disease prevalence, public and private investments to continuously improve medical infrastructure in the region.
Key players of this nuclear imaging equipment market include Agfa-Gevaert N.V, Cardiarc Ltd., Covidien Plc, Digirad Corporation, Gamma Medica Inc., Medx Inc., Naviscan Inc., Positron Corporation, Royal Philips Electronics, Segami Corporation, Siemens Healthcare, and Spectrum Dynamics Ltd.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Amongst the majorly used Covid-19 screening options, imaging is preferred by most healthcare professionals as it provides a primary diagnosis in a short time. All the imaging modalities including nuclear imaging have been used exhaustively to study Covid-19 and its effect on different patients in each demography. These are used in theories such as comparison of the vulnerability of pediatric and geriatric patients, and treatment response for several drug combinations. The rising requirement for advanced lung imaging solutions is expected to boost the development studies for lung phantoms. A detailed study on lung deterioration in Covid-19 patients is expected to provide advanced measures for early detection of the disease. The report will account for Covid19 as a key market contributor.